术前全身免疫炎症指数和血小板与淋巴细胞比值对卵巢来源腹膜癌转移的预后价值。
Prognostic value of pre-operative systemic immune-inflammation index and platelet to lymphocyte ratio in peritoneal carcinomatosis of ovarian origin.
机构信息
Department of Surgery, University Hospital Complex Badajoz, Av. de Elvas, s/n, 06080, Badajoz, Spain.
Department of Surgery, University Hospital Complex Badajoz, Av. de Elvas, s/n, 06080, Badajoz, Spain; Faculty of Medicine and Health Sciences, University of Extremadura, 06006, Badajoz, Spain.
出版信息
Surg Oncol. 2022 Jun;42:101750. doi: 10.1016/j.suronc.2022.101750. Epub 2022 Mar 30.
BACKGROUND AND OBJECTIVES
The aim of this study was to investigate the impact of systemic immune-inflammation index (SII), platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) on the survival outcomes of patients who underwent to cytoreductive surgery (CRS) and HIPEC for ovarian peritoneal carcinomatosis.
METHODS
A retrospective analysis of 68 cases following surgery at our department between 2015 and 2020 was performed. Receiver Operating Characteristic (ROC) curve was used with Youden index to calculate the optimal cutoff values for SII, PLR and NLR.
RESULTS
Univariate analysis revealed that high preoperative values of SII, PLR and NLR were correlated with worse overall survival (OS) and disease-free survival (DFS) in these patients. In the multivariable analysis, high SII was recognized as an independent prognostic factor for OS (CI 95%: 0.002- 3.835, p = 0.097) and high PLR was recognized as an independent prognostic factor for DFS (CI 95%: 0.253-2.248, p = 0.007).
CONCLUSION
SII and PLR could be useful prognostic tools to predict outcomes of patients who underwent to CRS and HIPEC for ovarian peritoneal carcinomatosis.
背景与目的
本研究旨在探讨全身免疫炎症指数（SII）、血小板与淋巴细胞比值（PLR）和中性粒细胞与淋巴细胞比值（NLR）对接受细胞减灭术（CRS）和腹腔热灌注化疗（HIPEC）治疗卵巢腹膜癌患者生存结局的影响。
方法
回顾性分析了 2015 年至 2020 年期间我科手术的 68 例患者。采用受试者工作特征（ROC）曲线，用约登指数计算 SII、PLR 和 NLR 的最佳截断值。
结果
单因素分析显示，术前 SII、PLR 和 NLR 较高与患者总生存（OS）和无病生存（DFS）较差相关。多因素分析显示，高 SII 是 OS 的独立预后因素（CI 95%：0.002-3.835，p=0.097），高 PLR 是 DFS 的独立预后因素（CI 95%：0.253-2.248，p=0.007）。
结论
SII 和 PLR 可作为预测接受 CRS 和 HIPEC 治疗卵巢腹膜癌患者结局的有用预后工具。
Zotero 插件